Processing

Please wait...

Settings

Settings

1. WO1991000105 - VACCINE AGAINST BOVINE LEUKEMIA VIRUS

Publication Number WO/1991/000105
Publication Date 10.01.1991
International Application No. PCT/FR1990/000456
International Filing Date 22.06.1990
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/15 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2740/13022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
13011Gammaretrovirus, e.g. murine leukeamia virus
13022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/13034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
13011Gammaretrovirus, e.g. murine leukeamia virus
13034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • RHONE MERIEUX [FR/FR]; 17, rue Bourgelat F-69002 Lyon, FR (AllExceptUS)
  • PORTETELLE, Daniel, Georges, Joseph, Ghislain [BE/BE]; BE (UsOnly)
  • BURNY, Arsène, Léon, Ghislain [BE/BE]; BE (UsOnly)
  • VONECHE, Véronique, Josette, Jacqueline, Marie [BE/BE]; BE (UsOnly)
Inventors
  • PORTETELLE, Daniel, Georges, Joseph, Ghislain; BE
  • BURNY, Arsène, Léon, Ghislain; BE
  • VONECHE, Véronique, Josette, Jacqueline, Marie; BE
Agents
  • LEMOINE, Michel ; Cabinet Lemoine et Bernasconi 13, bld des Batignolles F-75008 Paris, FR
Priority Data
89/0836823.06.1989FR
Publication Language French (FR)
Filing Language French (FR)
Designated States
Title
(EN) VACCINE AGAINST BOVINE LEUKEMIA VIRUS
(FR) VACCIN CONTRE LE VIRUS DE LA LEUCEMIE BOVINE
Abstract
(EN)
The vaccine against bovine leukemia virus (BLV) contains a peptide fraction, or a recombinant virus which express it, which includes the envelope glycoprotein gp51 of BLV virus and which leads to a high degree of neutralizing antibody formation. The gp51 glycoprotein is associated with a transmembrane glycoprotein or a specific monoclonal antibody of one of the epitopes of gp51, so that the gp51 glycoprotein is restored to its native configuration in which epitopes F, G and H are present, these epitopes being responsible for the biological activity of BLV virus, in a pharmaceutical vehicle or excipient such as those which are used to constitute vaccines.
(FR)
Le vaccin contre le virus de la leucémie bovine (BLV), comprend une fraction peptidique, ou un virus recombinant l'exprimant, qui inclut la glycoprotéine d'enveloppe gp51 du virus BLV et qui induit à un degré élevé la formation d'anticorps neutralisants. La glycoprotéine gp51 est associée à une glycoprotéine transmembranaire ou à un anticorps monoclonal spécifique de l'un des épitopes de la gp51, de manière à restituer à la glycoprotéine gp51 sa configuration native où sont présents les épitopes F, G et H responsables de l'activité biologique du virus BLV, dans un véhicule ou excipient pharmaceutique du type de ceux utilisés pour la constitution de vaccins.
Also published as
Other related publications
Latest bibliographic data on file with the International Bureau